Impact of Prevnar (PCV13) vaccine recommendations in pediatric and immunocompetent adults 65 years and older: What are the benefits and risks?

Authors

James E. Watkins, Providence St. Joseph HealthFollow
Anne Marie Thibodeaux, Providence St. Joseph HealthFollow
John C. Darnell, Providence St. Joseph HealthFollow

Document Type

Presentation

Publication Date

12-12-2019

Publication Title

PMG Oregon Nursing Conference, 12/12/19

Abstract

Background:

2000: PCV7 becomes the first FDA approved pneumococcal vaccine for pediatrics
2010: PCV13 recommended in pediatrics
2014: PCV13 recommended in immunocompetent adults 65+
2018: CDC looked at data since 2014 recommendation
2019: PCV13 now shared clinical decision-making

Clinical Institute

Women & Children

Department

Allergy & Immunology

Department

Pharmacy

Recommended Citation

Watkins, James E.; Thibodeaux, Anne Marie; and Darnell, John C., "Impact of Prevnar (PCV13) vaccine recommendations in pediatric and immunocompetent adults 65 years and older: What are the benefits and risks?" (2019). Articles, Abstracts, and Reports. 2876.
https://digitalcommons.providence.org/publications/2876